A
Arthur L. Weaver
Researcher at University of Nebraska Medical Center
Publications - 56
Citations - 10810
Arthur L. Weaver is an academic researcher from University of Nebraska Medical Center. The author has contributed to research in topics: Rheumatoid arthritis & Placebo. The author has an hindex of 32, co-authored 56 publications receiving 10644 citations. Previous affiliations of Arthur L. Weaver include University of Texas Southwestern Medical Center.
Papers
More filters
Journal ArticleDOI
A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
Joan M. Bathon,Richard J. Martin,Roy Fleischmann,John Tesser,Michael Schiff,Edward C. Keystone,Mark C. Genovese,Mary Chester M. Wasko,Larry W. Moreland,Arthur L. Weaver,Joseph A. Markenson,Barbara K. Finck +11 more
TL;DR: Subcutaneous [corrected] etanercept acted more rapidly to decrease symptoms and slow joint damage in patients with early active rheumatoid arthritis.
Journal ArticleDOI
Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.
Larry W. Moreland,Scott Baumgartner,Michael Schiff,Elizabeth A. Tindall,Roy Fleischmann,Arthur L. Weaver,Robert E. Ettlinger,Stanley Cohen,William J. Koopman,Kendall Mohler,Michael B. Widmer,Consuelo M. Blosch +11 more
TL;DR: In this three-month trial TNFR:Fc was safe, well tolerated, and associated with improvement in the inflammatory symptoms of rheumatoid arthritis.
Journal ArticleDOI
Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial
Larry W. Moreland,Michael Schiff,Scott Baumgartner,Elizabeth A. Tindall,Roy Fleischmann,Ken J. Bulpitt,Arthur L. Weaver,Edward C. Keystone,Daniel E. Furst,Philip J. Mease,Eric Ruderman,David A. Horwitz,Daniel G. Arkfeld,Leslie Garrison,Daniel Burge,Consuelo M. Blosch,Mary Lange,Neil D. McDonnell,Michael E. Weinblatt +18 more
TL;DR: In a phase II study, etanercept (recombinant human tumor necrosis factor receptor [p75]:Fc fusion protein) safely produced rapid, dose-dependent improvement in rheumatoid arthritis over 3 months as discussed by the authors.
Journal Article
Etanercept Therapy in Rheumatoid Arthritis
Larry W. Moreland,Michael Schiff,Scott Baumgartner,Elizabeth A. Tindall,Roy Fleischmann,Ken J. Bulpitt,Arthur L. Weaver,Edward C. Keystone,Daniel E. Furst,Philip J. Mease,Eric Ruderman,David A. Horwitz,Daniel G. Arkfeld,Leslie Garrison,Daniel Burge,Consuelo M. Blosch,Mary Lange,Neil D. McDonnell,Michael E. Weinblatt +18 more
TL;DR: This study sought to define further the clinical activity of etanercept over a longer treatment period and to establish a simplified dosing schema for rheumatoid arthritis.
Journal ArticleDOI
Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis : A randomized controlled trial
Lee S. Simon,Arthur L. Weaver,David Y. Graham,A J Kivitz,Peter E. Lipsky,Richard C. Hubbard,Peter C. Isakson,Kenneth M. Verburg,Shawn S. Yu,William W. Zhao,G S Geis +10 more
TL;DR: All dosages of celecoxib were efficacious in the treatment of rheumatoid arthritis and did not affect COX-1 activity in the GI tract mucosa as evidenced by less frequent incidence of endoscopic ulcers compared with naproxen.